Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 84Kidney Neoplasms 22Prostatic Neoplasms 14Neoplasm Metastasis 10Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Hepatocellular 5Liver Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma 3Urethral Neoplasms 2Sarcoma 2Multiple Myeloma 2Hematologic Neoplasms 2Glioblastoma 2Financial Stress 2Wilms Tumor 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypophosphatemia × Sorafenib × Genitourinary × Clear all
NCT00622479 2014-12-18

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Bayer

Phase 1 Terminated
12 enrolled
Genitourinary

Carcinoma, Renal Cell, Hypophosphatemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡